low-titer O-group whole blood

Phase 3Small molecule

low-titer O-group whole blood is one of 4 small molecule programs targeting Blood Transfusion. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Blood TransfusionNot yet recruiting

Blood TransfusionPhase 3

Not yet recruiting

Competition

Competitive Landscape

4 competitors in Blood Transfusion

#DrugCompanyPhaseTrials

Cyklokapron

JJ Molner

Approved

6 2

low-titer O-group whole blood

XXijing Hospital

Phase 3

1 3

HBOC-201

JJohns Hopkins University

Preclinical

1 4

Epsilon-Aminocaproic Acid (EACA)

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Not yet recruiting

Blood Transfusion

NCT07129031

Clinical

Trials by Indication[1]

Blood Transfusion1 trial

Optimization Strategies for Blood Transfusion Protocols in the Emergency Treatment of Hemorrhagic Shock

Not yet recruiting·XXijing Hospital·Phase 3·NCT07129031·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for low-titer O-group whole blood. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — low-titer O-group whole blood compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for low-titer O-group whole blood. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xijing Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: XXijing Hospital

low-titer O-group whole blood

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Blood Transfusion1 trial

References

Drug Info

Quick Facts

Related News